Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSD
Dates
study started
completion around
Principal Investigator
by Surbhi Singhal (ucdavis)

Description

Summary

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Official Title

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Details

Keywords

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Carcinoma, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Bevacizumab, Immunological Antineoplastic Agents, Osimertinib, Endothelial Growth Factors, Antibodies, Immunoglobulins, Monoclonal Antibodies, Immunoglobulin G, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Multigated Acquisition Scan, osimertinib, bevacizumab

Eligibility

Locations

Lead Scientist at University of California Health

  • Surbhi Singhal (ucdavis)
    Assistant Professor, MED: Int Med Hematology/Oncology, School of Medicine. Authored (or co-authored) 23 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT04181060
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 300 study participants
Last Updated